Clinical characteristics of AML ontogeny subtypes
. | De novo AML∗ (n = 116) . | t-AML∗ (n = 92) . | MR-Hx∗ (n = 107) . | MR-CG∗ (n = 29) . | P value† . |
---|---|---|---|---|---|
Age (y) | 60 (46-68) | 70 (61-75) | 69 (60-77) | 71 (60-77) | <.001 |
BM blast % | 56 (38-72) | 30 (21-48) | 30 (23-44) | 35 (25-55) | <.001 |
WBC (× 103/μL) | 6 (2-17) | 3 (2-8) | 2 (1-6) | 2 (1-4) | <.001 |
Platelets (× 103/μL) | 68 (37-128) | 50 (30-113) | 46 (22-106) | 37 (28-90) | .050 |
PB blast % | 27 (12-60) | 14 (3-25) | 8 (2-22) | 9 (4-18) | <.001 |
Gender | .024 | ||||
F | 55 (47%) | 45 (49%) | 37 (35%) | 7 (24%) | |
M | 61 (53%) | 47 (51%) | 70 (65%) | 22 (76%) | |
Previous history of nonmyeloid cancer | <.001 | ||||
No | 108 (93%) | 0 (0%) | 94 (88%) | 25 (86%) | |
Yes | 8 (6.9%) | 92 (100%) | 13 (12%) | 4 (14%) | |
History of chemo radiation | <.001 | ||||
No | 116 (100%) | 0 (0%) | 107 (100%) | 29 (100%) | |
Yes | 0 (0%) | 92 (100%) | 0 (0%) | 0 (0%) | |
History of MDS/MPN | <.001 | ||||
No | 116 (100%) | 50 (54%) | 0 (0%) | 29 (100%) | |
Yes | 0 (0%) | 42 (46%) | 107 (100%) | 0 (0%) | |
Transplant (allo-HSCT) | <.001 | ||||
No | 48 (41%) | 73 (79%) | 78 (73%) | 21 (72%) | |
Yes | 68 (59%) | 19 (21%) | 29 (27%) | 8 (28%) | |
Death | <.001 | ||||
No | 71 (61%) | 11 (12%) | 15 (14%) | 4 (14%) | |
Yes | 45 (39%) | 81 (88%) | 92 (86%) | 25 (86%) | |
CG risk group | <.001 | ||||
Favorable | 13 (11%) | 6 (6.5%) | 0 (0%) | 0 (0%) | |
Intermediate | 84 (72%) | 31 (34%) | 55 (51%) | 1 (3.4%) | |
Adverse | 6 (5.2%) | 49 (53%) | 51 (48%) | 28 (97%) | |
Cannot be assessed | 13 (11%) | 6 (6.5%) | 1 (0.9%) | 0 (0%) | |
ELN 2022 | <.001 | ||||
Favorable | 38 (33%) | 11 (12%) | 7 (6.5%) | 0 (0%) | |
Intermediate | 41 (35%) | 18 (20%) | 18 (17%) | 1 (3.4%) | |
Adverse | 37 (32%) | 63 (68%) | 82 (77%) | 28 (97%) | |
Treatment | <.001 | ||||
7+3 | 98 (84%) | 34 (37%) | 38 (36%) | 17 (59%) | |
Venetoclax + HMA/low DAC | 3 (2.6%) | 7 (7.6%) | 8 (7.5%) | 0 (0%) | |
HMA | 3 (2.6%) | 21 (23%) | 17 (16%) | 5 (17%) | |
Trial | 12 (10%) | 16 (17%) | 28 (26%) | 6 (21%) | |
None/supportive care | 0 (0%) | 14 (15%) | 16 (15%) | 1 (3.4%) | |
Best response pretransplant | <.001 | ||||
CR | 87 (75%) | 23 (25%) | 26 (24%) | 10 (34%) | |
CRi | 3 (2.6%) | 5 (5.4%) | 8 (7.5%) | 1 (3.4%) | |
Death/early death | 5 (4.3%) | 21 (23%) | 26 (24%) | 5 (17%) | |
MLFS | 2 (1.7%) | 4 (4.3%) | 3 (2.8%) | 1 (3.4%) | |
Persistent disease | 19 (16%) | 39 (42%) | 44 (41%) | 12 (41%) | |
MRD category (by flow) | .020 | ||||
CR/CRi MRD Neg | 55 (64%) | 11 (39%) | 13 (37%) | 5 (56%) | |
CR/CRi MRD Pos | 31 (36%) | 17 (61%) | 22 (63%) | 4 (44%) | |
Molecular group | <.001 | ||||
inv16, t(15;17), t(8;21) | 13 (68%) | 6 (32%) | 0 (0%) | 0 (0%) | |
CEBPA | 7 (64%) | 1 (9.1%) | 3 (27%) | 0 (0%) | |
NPM1 | 30 (70%) | 6 (14%) | 7 (16%) | 0 (0%) | |
MLL | 1 (10%) | 8 (80%) | 1 (10%) | 0 (0%) | |
t(6;9) | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) | |
EVI1 | 5 (28%) | 4 (22%) | 9 (50%) | 0 (0%) | |
TP53 | 1 (1.6%) | 35 (55%) | 12 (19%) | 16 (25%) | |
MR and/or RUNX1 | 29 (28%) | 17 (17%) | 51 (50%) | 5 (4.9%) | |
NOS | 24 (39%) | 11 (18%) | 19 (31%) | 8 (13%) | |
NEG | 5 (38%) | 3 (23%) | 5 (38%) | 0 (0%) |
. | De novo AML∗ (n = 116) . | t-AML∗ (n = 92) . | MR-Hx∗ (n = 107) . | MR-CG∗ (n = 29) . | P value† . |
---|---|---|---|---|---|
Age (y) | 60 (46-68) | 70 (61-75) | 69 (60-77) | 71 (60-77) | <.001 |
BM blast % | 56 (38-72) | 30 (21-48) | 30 (23-44) | 35 (25-55) | <.001 |
WBC (× 103/μL) | 6 (2-17) | 3 (2-8) | 2 (1-6) | 2 (1-4) | <.001 |
Platelets (× 103/μL) | 68 (37-128) | 50 (30-113) | 46 (22-106) | 37 (28-90) | .050 |
PB blast % | 27 (12-60) | 14 (3-25) | 8 (2-22) | 9 (4-18) | <.001 |
Gender | .024 | ||||
F | 55 (47%) | 45 (49%) | 37 (35%) | 7 (24%) | |
M | 61 (53%) | 47 (51%) | 70 (65%) | 22 (76%) | |
Previous history of nonmyeloid cancer | <.001 | ||||
No | 108 (93%) | 0 (0%) | 94 (88%) | 25 (86%) | |
Yes | 8 (6.9%) | 92 (100%) | 13 (12%) | 4 (14%) | |
History of chemo radiation | <.001 | ||||
No | 116 (100%) | 0 (0%) | 107 (100%) | 29 (100%) | |
Yes | 0 (0%) | 92 (100%) | 0 (0%) | 0 (0%) | |
History of MDS/MPN | <.001 | ||||
No | 116 (100%) | 50 (54%) | 0 (0%) | 29 (100%) | |
Yes | 0 (0%) | 42 (46%) | 107 (100%) | 0 (0%) | |
Transplant (allo-HSCT) | <.001 | ||||
No | 48 (41%) | 73 (79%) | 78 (73%) | 21 (72%) | |
Yes | 68 (59%) | 19 (21%) | 29 (27%) | 8 (28%) | |
Death | <.001 | ||||
No | 71 (61%) | 11 (12%) | 15 (14%) | 4 (14%) | |
Yes | 45 (39%) | 81 (88%) | 92 (86%) | 25 (86%) | |
CG risk group | <.001 | ||||
Favorable | 13 (11%) | 6 (6.5%) | 0 (0%) | 0 (0%) | |
Intermediate | 84 (72%) | 31 (34%) | 55 (51%) | 1 (3.4%) | |
Adverse | 6 (5.2%) | 49 (53%) | 51 (48%) | 28 (97%) | |
Cannot be assessed | 13 (11%) | 6 (6.5%) | 1 (0.9%) | 0 (0%) | |
ELN 2022 | <.001 | ||||
Favorable | 38 (33%) | 11 (12%) | 7 (6.5%) | 0 (0%) | |
Intermediate | 41 (35%) | 18 (20%) | 18 (17%) | 1 (3.4%) | |
Adverse | 37 (32%) | 63 (68%) | 82 (77%) | 28 (97%) | |
Treatment | <.001 | ||||
7+3 | 98 (84%) | 34 (37%) | 38 (36%) | 17 (59%) | |
Venetoclax + HMA/low DAC | 3 (2.6%) | 7 (7.6%) | 8 (7.5%) | 0 (0%) | |
HMA | 3 (2.6%) | 21 (23%) | 17 (16%) | 5 (17%) | |
Trial | 12 (10%) | 16 (17%) | 28 (26%) | 6 (21%) | |
None/supportive care | 0 (0%) | 14 (15%) | 16 (15%) | 1 (3.4%) | |
Best response pretransplant | <.001 | ||||
CR | 87 (75%) | 23 (25%) | 26 (24%) | 10 (34%) | |
CRi | 3 (2.6%) | 5 (5.4%) | 8 (7.5%) | 1 (3.4%) | |
Death/early death | 5 (4.3%) | 21 (23%) | 26 (24%) | 5 (17%) | |
MLFS | 2 (1.7%) | 4 (4.3%) | 3 (2.8%) | 1 (3.4%) | |
Persistent disease | 19 (16%) | 39 (42%) | 44 (41%) | 12 (41%) | |
MRD category (by flow) | .020 | ||||
CR/CRi MRD Neg | 55 (64%) | 11 (39%) | 13 (37%) | 5 (56%) | |
CR/CRi MRD Pos | 31 (36%) | 17 (61%) | 22 (63%) | 4 (44%) | |
Molecular group | <.001 | ||||
inv16, t(15;17), t(8;21) | 13 (68%) | 6 (32%) | 0 (0%) | 0 (0%) | |
CEBPA | 7 (64%) | 1 (9.1%) | 3 (27%) | 0 (0%) | |
NPM1 | 30 (70%) | 6 (14%) | 7 (16%) | 0 (0%) | |
MLL | 1 (10%) | 8 (80%) | 1 (10%) | 0 (0%) | |
t(6;9) | 1 (50%) | 1 (50%) | 0 (0%) | 0 (0%) | |
EVI1 | 5 (28%) | 4 (22%) | 9 (50%) | 0 (0%) | |
TP53 | 1 (1.6%) | 35 (55%) | 12 (19%) | 16 (25%) | |
MR and/or RUNX1 | 29 (28%) | 17 (17%) | 51 (50%) | 5 (4.9%) | |
NOS | 24 (39%) | 11 (18%) | 19 (31%) | 8 (13%) | |
NEG | 5 (38%) | 3 (23%) | 5 (38%) | 0 (0%) |
BM, bone marrow; CR, complete remission; CRi, complete remission with incomplete count recovery; DAC, dose cytarabine; F, female; HMA, hypomethylating agents; M, male; MLFS, morphological leukemia-free state; MRD, measurable residual disease; NOS, not otherwise specified; WBC, white blood cell.
Median (IQR); n (%).
Kruskal-Wallis rank-sum test; Pearson χ2 test; Fisher exact test for count data with simulated P value (based on 2000 replicates).